<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532337</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-5334POE003</org_study_id>
    <nct_id>NCT00532337</nct_id>
  </id_info>
  <brief_title>Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis</brief_title>
  <official_title>A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in
      postmenopausal women with osteopenia or osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean bone mineral density of the lumbar spine (L 1-4 BMD)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density at hip, Biochemical markers of bone turnover</measure>
    <time_frame>during course of treatment of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-5334</intervention_name>
    <description>Placebo - 24/mos.</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-5334</intervention_name>
    <description>100mg QD /24 months</description>
    <arm_group_label>E1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-5334</intervention_name>
    <description>50mg BID /24 mos.</description>
    <arm_group_label>E2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-5334</intervention_name>
    <description>300mg QD /24 mos.</description>
    <arm_group_label>E3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-5334</intervention_name>
    <description>Alendronate 70mg once weekly / 24 mos</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Osteoporosis defined as a value DXA BMD 2.5 SD or more below the young adult mean
        (T-score, ≤-2.5) at the lumbar spine (L1 to L4) or total hip, OR

          -  Osteoporosis defined as a value of DXA BMD more than 1 SD below the young adult mean,
             but less than 2.5 SD below this value (T-score &lt;-1 and &gt;2.5) at the lumbar spine (L1
             to L4) or total hip.

        Exclusion Criteria:

          1. Patients with a value of DXA BMD more that 3.5 SD below the young adult mean, (T-score
             &lt;-3.5) at the lumbar spine (L1 to L4) or total hip.

          2. Osteoporosis patients (T-score ≤-2.5) who have any vertebral fragility fracture
             between T4 and L4 inclusive.

          3. Osteopenia patients (T-score &lt;-1 and &gt;-2.5) who have no vertebral fragility fractures
             between T4 and L4 inclusive, OR

               -  Osteopenia patients (T-score &lt;-1 and &gt;-2.5) who have two or more vertebral
                  fragility fractures between T4 and L4 inclusive.

          4. Patients who have abnormalities of the lumbar spine or femoral neck or internal organs
             around them precluding the assessment of BMD.

          5. Patients who have secondary causes of osteoporosis or other disorders of bone and
             mineral metabolism.

          6. Other exclusion criteria as specified in the study protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomohiro Kuwayama</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andromed Noord Groningen</name>
      <address>
        <city>Damsterdiep 9</city>
        <state>Groningen</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ONO-5334</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>osteopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

